Sanofi (NYSE:SNY) posted its quarterly earnings data on Wednesday. The company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.07), Morningstar.com reports. Sanofi had a return on equity of 25.19% and a net margin of 25.44%. The business had revenue of $8.69 billion for the quarter, compared to the consensus estimate of $8.65 billion. During the same period in the previous year, the firm earned $1.25 EPS. The company’s revenue was down 2.1% on a year-over-year basis.
Shares of Sanofi (NYSE SNY) traded down $0.62 during trading on Thursday, reaching $39.77. 2,688,684 shares of the company’s stock traded hands, compared to its average volume of 2,350,667. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The stock has a market capitalization of $102,970.00, a PE ratio of 21.56, a PEG ratio of 2.43 and a beta of 0.85. Sanofi has a twelve month low of $39.59 and a twelve month high of $50.65.
A number of institutional investors have recently modified their holdings of the business. Moors & Cabot Inc. raised its holdings in Sanofi by 0.7% in the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock worth $311,000 after buying an additional 43 shares during the last quarter. Toronto Dominion Bank raised its holdings in shares of Sanofi by 4.6% during the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after purchasing an additional 180 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Sanofi by 7.0% during the second quarter. Quadrant Capital Group LLC now owns 5,909 shares of the company’s stock valued at $264,000 after purchasing an additional 384 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC raised its holdings in shares of Sanofi by 0.9% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 71,517 shares of the company’s stock valued at $3,426,000 after purchasing an additional 651 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Sanofi by 8.3% during the third quarter. BNP Paribas Arbitrage SA now owns 15,374 shares of the company’s stock valued at $765,000 after purchasing an additional 1,183 shares during the last quarter. 9.09% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.com-unik.info/2018/02/08/sanofi-sny-announces-quarterly-earnings-results-misses-expectations-by-0-07-eps.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.